Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
12 Dicembre 2022 - 12:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, announced today
that the Company was named the leading Proteomics Solutions Company
in the U.S. by Life Sciences Review
Magazine, featured in the December 2022 issue, “Top 10
Proteomics Solutions Companies of 2022.” Biodesix is a market
leader with over 15 years of experience in the field of clinical
proteomics. The Company’s expertise focuses on profiling the
patient’s immune response to their cancer with blood-based
proteomic solutions, in addition to genomic insights. Biodesix’s
core technologies and extensive machine learning and transparent AI
expertise allow for identifying clinically relevant proteomic
differences in patient populations to help guide treatment
strategy. To date, Biodesix has performed over 125,000 proteomic
tests for research and clinical use.
“We understand the importance of the circulating human proteome
as a vital component of the disease,” says Kieran O’Kane, Chief
Commercial Officer at Biodesix. “High-plex assays combine different
proteins into a single diagnostic test to ensure better outcomes.
We are honored to receive this recognition for our dedication to
proteomic insights for patients and would like to congratulate the
nine other esteemed proteomic solutions companies and teams
recognized.”
Biodesix currently offers three clinical proteomic tests, using
technologies such as Liquid Chromatography Mass Spectrometry
(LC-MS), MALDI-ToF Mass Spectrometry, and Enzyme-Linked
Immunosorbent Assay (ELISA). Nodify Lung® testing consists of two
blood-based proteomic tests, the Nodify CDT® and Nodify XL2® tests,
to help healthcare providers quickly decipher the risk of
malignancy of a lung nodule. The VeriStrat® proteomic test
identifies a chronic inflammatory disease state associated with
aggressive non-small cell lung cancer (NSCLC) in an average of
36-hour turnaround time without the need for tissue biopsy. The
VeriStrat proteomic test is part of the IQLung™ treatment guidance
testing strategy, which also includes the GeneStrat® targeted
genomic test and the GeneStrat NGS™ genomic test. IQLung testing
provides a broader view of each patient’s disease state, with
results delivered in average of 72 hours, empowering care teams
with test results that inform treatment decisions for any stage of
NSCLC.
The Top 10 Proteomics Solutions Companies digital issue is now
available at LifeSciencesReview.com, and the full Biodesix profile
can be found at www.lifesciencesreview.com/biodesix-inc.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in incidental pulmonary nodules, enabling
physicians to better triage patients to the most appropriate course
of action. The blood based IQLung™ strategy for lung cancer
patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an average of 36-72
hours, expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information about
Biodesix, visit www.biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221212005075/en/
Media: Kelly Mellott Kelly.Mellott@biodesix.com (303)
417-0500
Investors: Chris Brinzey chris.brinzey@westwicke.com
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Lug 2023 a Lug 2024